The Medical Letter on Drugs and Therapeutics
Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved abaloparatide (Tymlos – Radius Health), a synthetic analog of human parathyroid hormone related peptide, for treatment of postmenopausal women with osteoporosis who are at high risk for fracture. Abaloparatide is the second parathyroid hormone receptor agonist to be approved for this indication; teriparatide (Forteo – Lilly), a recombinant parathyroid hormone analog, was the first. They are the only drugs approved for treatment of osteoporosis that stimulate bone formation. Other drugs used for this indication inhibit bone resorption.1

ACTIVITY — Given continuously, human parathyroid hormone has a catabolic effect on bone, but when it is given once daily in low doses, bone formation predominates. Abaloparatide, like teriparatide, increases bone mineral density (BMD) and bone formation markers. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
Article code: 1523a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian